Key facts
- Evecxia Therapeutics’s last known valuation is $19.0M (Sep 2025).
- It has raised $32.0M.
- Notable investors include Bull City Venture Partners, Collage Venture Partners.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Evecxia Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Evecxia Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Evecxia Therapeutics
Operator of a biotechnology company intended to realize the therapeutic potential of amplifying serotonin synthesis for neuropsychiatric disorders. The company's technology sustained 5-HTP plasma levels and sustained brain serotonin amplification to treat brain disorders, such as depression, and acute suicidal ideation crises, enabling physicians with a drug that leverages risk-mitigated antidepressant augmentation pharmacology.
- Sector
- Healthcare
- HQ
- Durham, NC, United States
- Founded
- 2013
- Employees
- 2
- Website
- evecxia.com/
- Ownership
- Privately Held (backing)
Evecxia Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Evecxia Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Evecxia Therapeutics in its N-PORT filings yet. We sweep new filings monthly.